The AKT inhibitor Capivasertib (AZD5363): from discovery to clinical proof of concept – Dr Barry Davies, Global Project Leader, Oncology Combinations, Early Oncology, AstraZeneca.

When:
February 3, 2022 @ 9:30 am – 10:30 am
2022-02-03T09:30:00+00:00
2022-02-03T10:30:00+00:00
Where:
William Harvey Lecture Theatre
School of Clinical Medicine
Contact:
Justin Holt

Abstract not available

Leave a Reply

Your email address will not be published. Required fields are marked *